Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Immuneering Corporation (IMRX : NSDQ)

• Company Description    Immuneering Corporation is a biopharmaceutical company advancing a pipeline of oncology and neuroscience product candidates. The company's product candidate includes IMM-1-104. Immuneering Corporation is based in CAMBRIDGE, Mass. Number of Employees: 73

• Price / Volume Information    Yesterday's Closing Price: $9.42 Daily Weekly Monthly 20 Day Moving Average: 70,875 shares Shares Outstanding: 29.25 (millions) Market Capitalization: $275.52 (millions) Beta: -1.35 52 Week High: $16.17 52 Week Low: $3.70 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 17.31% 12.87% 12 Week 31.93% 22.47% Year To Date 94.23% 76.67%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 245 MAIN STREET SECOND FLOOR - CAMBRIDGE,MA 02142 USA ph: 617-500-8080 fax: - susan@sanoonan.com http://www.immuneering.com

• General Corporate Information    Officers Benjamin J. Zeskind, Ph.D. - Chief Executive Officer and President Mallory Morales - Vice President Finance and Treasurer Ann E. Berman - Director Robert J. Carpenter - Director Peter Feinberg ? - Director Peer Information Immuneering Corporation (CORR.) Immuneering Corporation (RSPI) Immuneering Corporation (CGXP) Immuneering Corporation (BGEN) Immuneering Corporation (GTBP) Immuneering Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45254E107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/09/23 Share - Related Items Shares Outstanding: 29.25 Most Recent Split Date: (:1) Beta: -1.35 Market Capitalization: $275.52 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.54 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.14 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/09/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.82 Price/Cash Flow: - Price / Sales: 869.17 EPS Growth vs. Year Ago Period: -4.08% vs. Previous Quarter: -2.00% Sales Growth vs. Year Ago Period: -99.47% vs. Previous Quarter: -97.37% ROE 03/31/23 - -44.23 12/31/22 - -39.66 09/30/22 - -34.59 ROA 03/31/23 - -40.50 12/31/22 - -36.69 09/30/22 - -32.30 Current Ratio 03/31/23 - 17.05 12/31/22 - 13.50 09/30/22 - 16.54 Quick Ratio 03/31/23 - 17.05 12/31/22 - 13.50 09/30/22 - 16.54 Operating Margin 03/31/23 - - 12/31/22 - -15,932.49 09/30/22 - -9,494.86 Net Margin 03/31/23 - - 12/31/22 - -15,934.70 09/30/22 - -9,496.25 Pre-Tax Margin 03/31/23 - -38,512.78 12/31/22 - -15,935.02 09/30/22 - -9,556.92 Book Value 03/31/23 - 3.34 12/31/22 - 4.16 09/30/22 - 4.62 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00 Debt-to-Capital 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00

Powered by Zacks Investment Research ©